7 news items
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
exclusivity of certain products; regulatory changes that result in lower prices, lower reimbursement rates and smaller populations for whom payers
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY
2 Apr 24
by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the outcome of pricing and reimbursement negotiations
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
BMY
CATX
LNTH
28 Mar 24
and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company's actual results to differ materially
Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY
20 Mar 24
available in the EU for this indication, including completion of reimbursement procedures.
Based on the KarMMa
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
7 Mar 24
patient access and reimbursement program, is designed to help appropriate patients initiate and maintain access to BMS medicines during their treatment
- Prev
- 1
- Next